Ketamine and the Suicidal Window: A Fast Bridge Across a Dangerous Gap

Key Takeaways:

• In an individual participant data meta-analysis of 10 controlled studies including 167 people who had suicidal ideation at baseline, a single intravenous dose of ketamine reduced suicidal ideation within one day compared with saline or midazolam, with moderate to large effect sizes (Cohen’s d 0.48 to 0.85) over the following week.
• In a randomized trial of 80 adults with major depression and clinically significant suicidal ideation, 55% of those given ketamine and 30% of those given the active control midazolam had at least a 50% drop in suicidal ideation scores 24 hours after the infusion, a number needed to treat of four.
• In rats, ketamine rapidly switched on the mTOR signaling pathway and increased the number and function of new synaptic spines in the prefrontal cortex, and blocking mTOR abolished both the new synapses and the antidepressant-like behavior; this animal work explains the speed but has not been directly confirmed in human brains.

October 10 is World Mental Health Day, and one of the hardest problems in all of mental health care is a problem of timing. Standard antidepressants take several weeks to work, and for a person in a suicidal crisis, those weeks are the most dangerous stretch of all. That lag is exactly why ketamine for suicidal thoughts has drawn so much attention. Ketamine is an anesthetic that blocks the NMDA receptor, one of the brain’s main receptors for the excitatory neurotransmitter glutamate. In 2006, a small but carefully designed crossover trial at the National Institute of Mental Health gave eighteen people with treatment-resistant major depression a single low-dose intravenous infusion of ketamine or a placebo. Depression scores improved significantly within 110 minutes of the ketamine infusion, and the benefit remained significant through the following week. For a field accustomed to measuring response in weeks, a response measured in hours was a genuine surprise, and it pointed toward a biology of depression that the older drugs, which act mainly on serotonin and norepinephrine, had never touched.

The leading explanation for that speed runs through a paradox. Blocking an excitatory receptor ought to quiet the brain, yet NMDA blockers produce cortical excitation. Recordings in awake rats showed why: NMDA inhibition predominantly silenced GABA-releasing inhibitory interneurons in the prefrontal cortex, and with that brake released, the firing of most pyramidal neurons rose. The result is a surge of glutamate release onto other receptors. In rats given ketamine, that surge rapidly activated the mTOR pathway, a master regulator of protein synthesis, which increased synaptic signaling proteins and the number and function of new dendritic spine synapses in the prefrontal cortex, reversing the kind of synaptic loss that chronic stress produces; when mTOR was blocked, both the new synapses and the antidepressant-like behavior disappeared. That mechanism comes from animal studies, but the human clinical signal is consistent with it. Pooling individual data from ten controlled studies, 167 participants with suicidal ideation at baseline saw that ideation fall within a single day after one ketamine dose, with moderate to large effects lasting up to a week. In a separate randomized trial of eighty depressed adults with clinically significant suicidal thoughts, ketamine outperformed midazolam, a sedative chosen so that participants could not easily tell which drug they had received, at 24 hours.

Is ketamine for suicidal thoughts a replacement for ongoing care?

No, and that distinction is the whole point. Ketamine is best understood as a bridge: a way to lower acute suicidal distress quickly while slower, durable treatments take hold. The studies measured suicidal thoughts over days to weeks, not suicide attempts or deaths over months, and the benefit of a single infusion was tracked only for about a week and is generally temporary. In the midazolam-controlled trial, improvement held for up to six weeks only because participants went on to receive optimized standard medication treatment afterward. Ketamine also carries real risks, including temporary dissociation, rises in blood pressure, and the potential for misuse, which is why it is given in monitored medical settings with screening beforehand and observation afterward; a nasal form, esketamine, is likewise administered only under supervision in certified settings. It should never be self-sourced, obtained online, or used without a treating clinician, and it is not appropriate for everyone. The durable work happens around it: psychotherapy, a written safety plan, reducing access to lethal means, continuing medication, and people who check in. If you or someone you love is thinking about suicide, help is available right now by calling or texting 988, the Suicide and Crisis Lifeline, any hour of the day.

References:

1. Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856-864.
2. Homayoun, H., & Moghaddam, B. (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience, 27(43), 11496-11500.
3. Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959-964.
4. Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. American Journal of Psychiatry, 175(2), 150-158.
5. Grunebaum, M. F., Galfalvy, H. C., Choo, T. H., Keilp, J. G., Moitra, V. K., Parris, M. S., et al. (2018). Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial. American Journal of Psychiatry, 175(4), 327-335.